GB0214784D0 - Novel combination - Google Patents

Novel combination

Info

Publication number
GB0214784D0
GB0214784D0 GBGB0214784.1A GB0214784A GB0214784D0 GB 0214784 D0 GB0214784 D0 GB 0214784D0 GB 0214784 A GB0214784 A GB 0214784A GB 0214784 D0 GB0214784 D0 GB 0214784D0
Authority
GB
United Kingdom
Prior art keywords
novel combination
novel
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0214784.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Ltd Great Britain
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Pfizer Inc filed Critical Pfizer Ltd Great Britain
Priority to GBGB0214784.1A priority Critical patent/GB0214784D0/en
Publication of GB0214784D0 publication Critical patent/GB0214784D0/en
Priority to GT200300124A priority patent/GT200300124A/es
Priority to PA20038575501A priority patent/PA8575501A1/es
Priority to RU2004136276/15A priority patent/RU2004136276A/ru
Priority to EP03761725A priority patent/EP1524996A2/en
Priority to JP2004517093A priority patent/JP2005531627A/ja
Priority to CN03814574XA priority patent/CN1662257A/zh
Priority to MXPA04012569A priority patent/MXPA04012569A/es
Priority to PCT/IB2003/002657 priority patent/WO2004002461A2/en
Priority to KR10-2004-7021041A priority patent/KR20050013156A/ko
Priority to CA002491002A priority patent/CA2491002A1/en
Priority to PL03375079A priority patent/PL375079A1/xx
Priority to AU2003242895A priority patent/AU2003242895A1/en
Priority to BR0312030-9A priority patent/BR0312030A/pt
Priority to TW092116851A priority patent/TW200404546A/zh
Priority to ARP030102252A priority patent/AR040337A1/es
Priority to PE2003000636A priority patent/PE20040868A1/es
Priority to UY27863A priority patent/UY27863A1/es
Priority to US10/603,369 priority patent/US20040132731A1/en
Priority to ZA200409532A priority patent/ZA200409532B/en
Priority to NO20050400A priority patent/NO20050400L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0214784.1A 2002-06-26 2002-06-26 Novel combination Ceased GB0214784D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
GT200300124A GT200300124A (es) 2002-06-26 2003-06-04 Nueva combinacion
PA20038575501A PA8575501A1 (es) 2002-06-26 2003-06-13 Nueva combinacion
BR0312030-9A BR0312030A (pt) 2002-06-26 2003-06-16 Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii
CA002491002A CA2491002A1 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists
AU2003242895A AU2003242895A1 (en) 2002-06-26 2003-06-16 Combination of PDE5 inhibitors with angiotensin II receptor antagonists
JP2004517093A JP2005531627A (ja) 2002-06-26 2003-06-16 新規混合医薬
CN03814574XA CN1662257A (zh) 2002-06-26 2003-06-16 Pde5抑制剂与血管紧张肽ⅱ受体拮抗剂的联用药物
MXPA04012569A MXPA04012569A (es) 2002-06-26 2003-06-16 Combinacion de inhibidores de fosfodiesteresa tipo 5(pde5) con antagonistas del receptor de angiotensina ii.
PCT/IB2003/002657 WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists
KR10-2004-7021041A KR20050013156A (ko) 2002-06-26 2003-06-16 신규 조합 제제
RU2004136276/15A RU2004136276A (ru) 2002-06-26 2003-06-16 Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11
PL03375079A PL375079A1 (en) 2002-06-26 2003-06-16 Novel combination
EP03761725A EP1524996A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists
TW092116851A TW200404546A (en) 2002-06-26 2003-06-20 Novel combination
ARP030102252A AR040337A1 (es) 2002-06-26 2003-06-24 Uso de una combinacion de un inhibidor de fosfodiesterasa tipo 5 (pde5) especifica de monofosfato de guanosina ciclico (gmpc) y un antagonista del receptor de angiotensina ii para preparar un medicamento
PE2003000636A PE20040868A1 (es) 2002-06-26 2003-06-24 Nueva combinacion de inhibidor de fosfodiesterasa de tipo 5 (pde5) y antagonista del receptor de angiotensina ii
UY27863A UY27863A1 (es) 2002-06-26 2003-06-24 Nueva combinacion
US10/603,369 US20040132731A1 (en) 2002-06-26 2003-06-25 Novel combination
ZA200409532A ZA200409532B (en) 2002-06-26 2004-11-25 Novel combination
NO20050400A NO20050400L (no) 2002-06-26 2005-01-25 Nytt kombinasjonspreparat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Publications (1)

Publication Number Publication Date
GB0214784D0 true GB0214784D0 (en) 2002-08-07

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0214784.1A Ceased GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Country Status (20)

Country Link
EP (1) EP1524996A2 (https=)
JP (1) JP2005531627A (https=)
KR (1) KR20050013156A (https=)
CN (1) CN1662257A (https=)
AR (1) AR040337A1 (https=)
AU (1) AU2003242895A1 (https=)
BR (1) BR0312030A (https=)
CA (1) CA2491002A1 (https=)
GB (1) GB0214784D0 (https=)
GT (1) GT200300124A (https=)
MX (1) MXPA04012569A (https=)
NO (1) NO20050400L (https=)
PA (1) PA8575501A1 (https=)
PE (1) PE20040868A1 (https=)
PL (1) PL375079A1 (https=)
RU (1) RU2004136276A (https=)
TW (1) TW200404546A (https=)
UY (1) UY27863A1 (https=)
WO (1) WO2004002461A2 (https=)
ZA (1) ZA200409532B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
EP2433555A3 (en) * 2002-07-26 2013-01-16 Olympus Corporation Image processing system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
ES2376628T3 (es) 2005-06-10 2012-03-15 Dong-A Pharmaceutical Co., Ltd. Agente para la prevención y el tratamiento de las enfermedades hep�?ticas que contiene un dirivado pirazolopirimidina.
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
EP1940389A2 (en) * 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
RU2345763C1 (ru) * 2007-04-26 2009-02-10 ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Also Published As

Publication number Publication date
ZA200409532B (en) 2006-06-28
CN1662257A (zh) 2005-08-31
PE20040868A1 (es) 2004-11-25
MXPA04012569A (es) 2005-04-19
AU2003242895A1 (en) 2004-01-19
RU2004136276A (ru) 2005-09-10
KR20050013156A (ko) 2005-02-02
JP2005531627A (ja) 2005-10-20
BR0312030A (pt) 2005-03-22
AR040337A1 (es) 2005-03-30
GT200300124A (es) 2004-03-17
NO20050400L (no) 2005-03-29
WO2004002461A3 (en) 2004-05-13
EP1524996A2 (en) 2005-04-27
PL375079A1 (en) 2005-11-14
PA8575501A1 (es) 2003-12-30
UY27863A1 (es) 2003-12-31
WO2004002461A2 (en) 2004-01-08
TW200404546A (en) 2004-04-01
CA2491002A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
DE50312422D1 (en) Aryloxime
IL166084A0 (en) Novel benzodioxoles
PL371678A1 (en) Novel pyridin- and pyrimidin-derivatives
PL373598A1 (en) Novel benzonaphthyridines
AU2003297193A8 (en) Meta-web
IL163529A0 (en) Novel spinosyn-producing polyketidesynthases
AU2003279495A8 (en) Alert-modeling
DE50303619D1 (en) Reibschweissvorrichtung
DE50308027D1 (en) Cyclohexyl-harnstoff-derivate
DE50307787D1 (en) Isophthalsäurederivate
DE50311133D1 (en) Carbonsäureamide
DE50312412D1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative
IL164975A0 (en) Novel combination
AU2003264900A8 (en) Cast-cutter
DE50310169D1 (en) Lingual-retainer
DE50304964D1 (en) Handhobelmaschine
GB0214784D0 (en) Novel combination
AU2002367810A8 (en) Bis-transition-metal-chelate-probes
GB0225873D0 (en) Combination
DE10392833D2 (en) Geotextilie
AU2003253735A8 (en) Vacuolins
DE50309021D1 (en) Etherlacton
GB0229743D0 (en) Novel benzoxazocines
GB0225874D0 (en) Combination
GB0225875D0 (en) Combination

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)